Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial will evaluate the combination of bevacizumab + RAD001 in patients with
metastatic renal cell carcinoma. In this trial the investigators will evaluate this
combination in patients previously untreated with any anti-angiogenesis agent and patients
who have previously received one prior regimen containing an anti-angiogenesis agent.